The mesenchyme in cancer therapy as a target tumor component, effector cell modality and cytokine expression vehicle

ISSN： 0167-7659

Source： Cancer and Metastasis Reviews, Vol.25, Iss.3, 2006-09, pp. : 459-467

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cytokine therapy in renal cell cancer

By Vuky J. Motzer R.J.

Urologic Oncology: Seminars and Original Investigations, Vol. 5, Iss. 6, 2000-11 ,pp. : 249-257

Elsevier

Access to resources Recommend Favorite

Downregulation of survivin expression by induction of the effector cell protease receptor-1 reduces tumor growth potential and results in an increased sensitivity to anticancer agents in human colon cancer

By Yamamoto T. Manome Y. Nakamura M. Tanigawa N.

European Journal of Cancer, Vol. 38, Iss. 17, 2002-11 ,pp. : 2316-2324

Elsevier

Access to resources Recommend Favorite

Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment

By Ito Koichi

Cancer and Metastasis Reviews, Vol. 31, Iss. 3-4, 2012-12 ,pp. : 763-778

Springer Publishing Company

Access to resources Recommend Favorite

Comparative Analysis of Current Modality of Therapy in Head and Neck Squamous Cell Carcinoma Correlating the Expression Level of p38

Current Cancer Therapy Reviews, Vol. 10, Iss. 3, 2014-08 ,pp. : 219-224

Bentham Science Publishers

Access to resources Recommend Favorite

Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET

By Negrier S. Jäger E. Porta C. McDermott D. Moore M. Bellmunt J. Anderson S. Cihon F. Lewis J. Escudier B. Bukowski R.

Medical Oncology, Vol. 27, Iss. 3, 2010-09 ,pp. : 899-906

Humana Press, Inc

Access to resources Recommend Favorite